AmpC β-lactamases detected in Southeast Asian Escherichia coli and Klebsiella pneumoniae
2024

AmpC β-lactamases in Southeast Asian E. coli and K. pneumoniae

Sample size: 126 publication Evidence: moderate

Author Information

Author(s): Tamalee Roberts, Clare L. Ling, Wanitda Watthanaworawit, Chanvoleak Cheav, Amphonesavanh Sengduangphachanh, Joy Silisouk, Jill Hopkins, Koukeo Phommasone, Elizabeth M. Batty, Paul Turner, Elizabeth A. Ashley

Primary Institution: Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford

Hypothesis

What is the prevalence of AmpC β-lactamase-producing E. coli and Klebsiella pneumoniae in Southeast Asia?

Conclusion

AmpC and inducible AmpC β-lactamases are important causes of infection in Southeast Asia, often going undetected with current testing methods.

Supporting Evidence

  • 31 out of 126 isolates were phenotypically AmpC positive.
  • All inducible AmpC isolates were ceftriaxone susceptible.
  • 97.7% of AmpC/inducible AmpC isolates tested against cefoxitin were resistant.
  • 12 different β-lactamase resistance genes were detected.
  • Cefoxitin screening is part of EUCAST guidelines.

Takeaway

Some germs in Southeast Asia can resist important medicines, making it hard to treat infections. We need better tests to find these germs.

Methodology

The study screened clinical isolates for AmpC β-lactamase production using MASTDISCS and whole-genome sequencing.

Potential Biases

Quality control was not thorough due to the absence of appropriate control strains at all sites.

Limitations

Different testing methods were used across sites, and not all isolates were sequenced due to financial constraints.

Participant Demographics

Isolates were collected from three clinical research sites in Cambodia, Laos, and Thailand.

Digital Object Identifier (DOI)

10.1093/jacamr/dlae195

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication